Compare KARO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | NRIX |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2020 | 2020 |
| Metric | KARO | NRIX |
|---|---|---|
| Price | $47.27 | $16.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $59.33 | $30.50 |
| AVG Volume (30 Days) | 82.1K | ★ 2.3M |
| Earning Date | 05-15-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $22.17 | N/A |
| Revenue Next Year | $16.74 | $48.05 |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $41.25 | $8.20 |
| 52 Week High | $60.53 | $22.50 |
| Indicator | KARO | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 56.04 |
| Support Level | $43.31 | $16.81 |
| Resistance Level | $47.79 | $17.23 |
| Average True Range (ATR) | 2.16 | 1.26 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 44.52 | 61.03 |
Karooooo Ltd is a provider of real-time mobility data analytics solutions for smart transportation. It offers a comprehensive, cloud-based smart mobility platform for connected vehicles and other assets. The company's software-as-a-service platform provides customers with differentiated insights and analytics to optimize business and workforce, increase efficiency and decrease costs, improve safety, monitor environmental impact, assist with regularity compliance, and manage risk. The segments of the group are Cartrack; Carzuka; and Karooooo Logistics, of which key revenue is derived from the Cartrack segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.